Positive Phase 3 INDIGO data for obexelimab in IgG4-related disease, followed by a sizeable share purchase by CEO Leon Moulder, has put Zenas BioPharma (ZBIO) firmly on investors’ radar this week.

The latest Phase 3 INDIGO readout and CEO share purchase come after a volatile stretch, with a 30 day share price return of 38.22% offsetting a 90 day share price decline of 37.49%, while the 1 year total shareholder return of 167.64% highlights how powerful news driven moves have been around Zenas BioPharma.

If this kind of biotech catalyst has your attention, it could be a good time to check out our screener of other healthcare names using AI, starting with 25 healthcare AI stocks.

With the stock still trading well below the average analyst price target and fresh Phase 3 data now public, the key question is whether Zenas BioPharma is mispriced or if the market is already factoring in potential future growth.

Preferred Price to Book of 5.7x: Is It Justified?

On a P/B of 5.7x, Zenas BioPharma trades at a richer level than the broader US biotechs sector, even though the company is still loss making.

P/B compares the market value of the company to its book value. In this case it is one of the few usable yardsticks given Zenas BioPharma is unprofitable and early in its commercial journey. For clinical stage biotechs, a higher P/B often reflects the market placing value on the pipeline and expected future cash flows rather than current earnings.

Against the wider US biotechs industry average of 2.6x, Zenas BioPharma looks expensive, which suggests investors are placing a relatively high value on its assets and programs. However, compared with a closer peer set on 7.8x, the same 5.7x multiple looks more conservative, hinting that expectations for Zenas BioPharma sit between broad sector sentiment and the tighter peer group, rather than at the very top of the range.

Result: Price-to-book of 5.7x (ABOUT RIGHT)

However, you still have to weigh the clear clinical risk around obexelimab’s broader indications and the company’s $189.899m net loss against today’s valuation.

Build Your Own Zenas BioPharma Narrative

If you see the numbers differently or prefer to piece together your own view from the raw data, you can build a personalised thesis in just a few minutes by starting with Do it your way.

A great starting point for your Zenas BioPharma research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Zenas has sharpened your interest in what is possible with focused research, do not stop here, broaden your watchlist with a few targeted screens.

• Hunt for overlooked quality by scanning our screener containing 25 high quality undiscovered gems that pair solid fundamentals with limited market attention.
• Prioritise resilience by checking companies in the 79 resilient stocks with low risk scores that score well on stability and risk metrics.
• Target financial strength by reviewing our solid balance sheet and fundamentals stocks screener (46 results) for businesses with healthier balance sheets and cleaner finances.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.